Compare Monster Beverage Corp (MNST) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs ResMed Inc. — how do they compare? Monster Beverage Corp trades at $43.56 (market cap $85.51B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: Monster Beverage Corp is far larger — about 2.7× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and ResMed Inc. for 51 Days on average.
| MNST | RMD | |
|---|---|---|
Market Cap | $85.51B | $31.89B |
Volume | 8,569,709 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $277.88 |
52-Week Low | $33.16 | $182.82 |
Typical Hold Time | 72 Days | 51 Days |
Enterprise Value | $83.81B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS of $0.30 beat estimates, revenue grew to $8.29 billion in 2025, and net income margin stands at 23.08%. A 1:2 stock split is scheduled for August 11, 2026. Analyst consensus is a 'Buy' with a $98.22 price target, but technical indicators show selling pressure near current levels.
The outlook for MNST is mixed: robust earnings growth and zero long-term debt support upside, but high valuation ratios (P/E of 40.42) and bearish technicals pose near-term risks. International expansion, particularly a 35% sales surge overseas, offers growth potential, though regulatory challenges in markets like India and inflation pressures could hinder performance. The stock's rich pricing requires sustained execution to justify further gains.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
